scholarly journals Human Plasma Metabolomics for Biomarker Discovery: Targeting the Molecular Subtypes in Breast Cancer

Cancers ◽  
2021 ◽  
Vol 13 (1) ◽  
pp. 147
Author(s):  
Leticia Díaz-Beltrán ◽  
Carmen González-Olmedo ◽  
Natalia Luque-Caro ◽  
Caridad Díaz ◽  
Ariadna Martín-Blázquez ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Biomarker Discovery ◽  
Molecular Subtypes ◽  
Breast Cancer Subtype ◽  
P Value ◽  
Plasma Samples ◽  
Breast Cancer Patients ◽  
Clinical Value ◽  
Molecular Phenotypes

Purpose: The aim of this study is to identify differential metabolomic signatures in plasma samples of distinct subtypes of breast cancer patients that could be used in clinical practice as diagnostic biomarkers for these molecular phenotypes and to provide a more individualized and accurate therapeutic procedure. Methods: Untargeted LC-HRMS metabolomics approach in positive and negative electrospray ionization mode was used to analyze plasma samples from LA, LB, HER2+ and TN breast cancer patients and healthy controls in order to determine specific metabolomic profiles through univariate and multivariate statistical data analysis. Results: We tentatively identified altered metabolites displaying concentration variations among the four breast cancer molecular subtypes. We found a biomarker panel of 5 candidates in LA, 7 in LB, 5 in HER2 and 3 in TN that were able to discriminate each breast cancer subtype with a false discovery range corrected p-value < 0.05 and a fold-change cutoff value > 1.3. The model clinical value was evaluated with the AUROC, providing diagnostic capacities above 0.85. Conclusion: Our study identifies metabolic profiling differences in molecular phenotypes of breast cancer. This may represent a key step towards therapy improvement in personalized medicine and prioritization of tailored therapeutic intervention strategies.

Association of dyslipidemia with the aggressive molecular subtypes and pathologic profile of newly diagnosed nonmetastatic breast cancer patients.

2012 ◽  
Vol 30 (27_suppl) ◽  
pp. 19-19
Author(s):  
Herdee Gloriane Cristal Luna ◽  
Cher Alaine Cristal Luna ◽  
Gloria R. Cristal-Luna ◽  
Cesar Vilela Luna
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Molecular Subtypes ◽  
Postmenopausal Breast Cancer ◽  
P Value ◽  
Fisher Exact Test ◽  
Breast Cancer Patients ◽  
Cancer Aggressiveness ◽  
Her 2 ◽  
Post Menopausal

19 Background: To investigate the association of dyslipidemia with the aggressive pathologic profile and molecular subtypes among the premenopausal and postmenopausal breast cancer patients. Methods: A retrospective review of Filipino breast cancer patients from 1990 to 2010 from an oncology clinic was done. Patients were grouped to pre- and post-menopausal and each group were divided to those with and without dyslipidemia. Association of dyslipidemia with breast cancer aggressiveness, (1) by pathology (histopathologic diagnosis, grade, invasion, TNM stage) and (2) by molecular phenotype (using the hormone status: estrogen and progesterone receptor positivity) and HER-2 neu status (overexpression by immunohistochemical stain / gene amplification by fluorescent in situ hybridization), was assessed using Fisher exact test. Results: Among 728 breast cancer patients, 201 met the inclusion criteria with 103 premenopausal (36 with dyslipidemia, 67 without dyslipidemia) and 98 were postmenopausal (42 with dyslipidemia, 56 without dyslipidemia). Significant association was noted only among pre-menopausal in terms of the molecular phenotypes (p value 0.002) when compared to individual parameters: total cholesterol (p value <0.001), LDL (p value <0.001), HDL (p value 0.006), and triglyceride (p value <0.001). Conclusions: Dyslipidemia was not found to be a factor associated with aggressiveness of breast cancer in terms of the pathology for both pre-menopausal and post-menopausal groups. Only among premenopausal patients was dyslipidemia shown to be a significant marker of aggressiveness in terms of poorer molecular subset (luminal B, HER-2, basal like). This finding was not observed among post-menopausal group.

CHANGES IN THE NIPPLE-AREOLA COMPLEX IN PATIENTS WITH BREAST CANCER

2017 ◽  
Vol 63 (4) ◽  
pp. 593-597
Author(s):  
Aziz Zikiryakhodzhaev ◽  
Nadezhda Volchenko ◽  
Erik Saribekyan ◽  
Yelena Rasskazova
Keyword(s):  
Breast Cancer ◽  
Surgical Treatment ◽  
Cancer Patients ◽  
Molecular Subtypes ◽  
Breast Cancer Patients ◽  
Nipple Areola Complex ◽  
Histological Types ◽  
Areola Complex

The article presents data about the lesion of the nipple-areola complex in breast cancer. In 2015-2016 surgical treatment was performed in 101 breast cancer patients, different in size but with the mandatory removal of the nipple-areola complex. There are analyzed the dependence of the lesion of the nipple-areola complex from histological types of breast cancer, molecular subtypes, multicentricity, the location of tumor in the breast. The most significant criterion was the dependence of the lesion of the nipple-areola complex from the distance between tumor node and the nipple.

Correlation of AGR2 expression with the incidence of metastasis in luminal breast cancer

2021 ◽  
pp. 1-5
Author(s):  
David Samuel Kereh ◽  
John Pieter ◽  
William Hamdani ◽  
Haryasena Haryasena ◽  
Daniel Sampepajung ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Mean Value ◽  
Rank Test ◽  
Luminal Breast Cancer ◽  
P Value ◽  
Strong Positive Correlation ◽  
Breast Cancer Patients ◽  
The Mean ◽  
Spearman Test

BACKGROUND: AGR2 expression is associated with luminal breast cancer. Overexpression of AGR2 is a predictor of poor prognosis. Several studies have found correlations between AGR2 in disseminated tumor cells (DTCs) in breast cancer patients. OBJECTIVE: This study aims to determine the correlation between anterior Gradient2 (AGR2) expression with the incidence of distant metastases in luminal breast cancer. METHODS: This study was an observational study using a cross-sectional method and was conducted at Wahidin Sudirohusodo Hospital and the network. ELISA methods examine AGR2 expression from blood serum of breast cancer patients. To compare the AGR2 expression in metastatic patients and the non-metastatic patient was tested with Mann Whitney test. The correlation of AGR2 expression and metastasis was tested with the Rank Spearman test. RESULTS: The mean value of AGR2 antibody expression on ELISA in this study was 2.90 ± 1.82 ng/dl, and its cut-off point was 2.1 ng/dl. Based on this cut-off point value, 14 subjects (66.7%) had overexpression of AGR2 serum ELISA, and 7 subjects (33.3%) had not. The mean value AGR2 was significantly higher in metastatic than not metastatic, 3.77 versus 1.76 (p < 0.01). The Spearman rank test obtained a p-value for the 2 tail test of 0.003 (p < 0.05), which showed a significant correlation of both, while the correlation coefficient of 0.612 showed a strong positive correlation of AGR2 overexpression and metastasis. CONCLUSIONS: AGR2 expression is correlated with metastasis in Luminal breast cancer.

scholarly journals Roles of Superoxide dismutase(SOD) , Malondialdehyde (MDA), 8-iso-prostaglandinF2α ( 8-iso-PGF2α)as oxidative stress in development and progression of Brest cancer in Iraqi females patients

2020 ◽  
Vol 25 (1) ◽  
pp. 1-4
Author(s):  
Ferdous Abbas Jabir ◽  
Ahmed Sabah Shaker
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Cancer Patients ◽  
Antioxidant Defenses ◽  
Blood Levels ◽  
P Value ◽  
Oxygen Species ◽  
Breast Cancer Patients ◽  
Markers Of Oxidative Stress ◽  
The Mean

               Oxidative stress occurs as a result of disturbance in the balance between the production of reactive oxygen species (free radicals) and antioxidant defenses. Markers of oxidative stress were measured the markers of oxidative stress in breast cancer patients after diagnosis of breast cancer and compared these plasma blood levels controls This study was conducted to three markers of oxidative stress ;these are (SOD) enzyme ,malondialdehyde (MDA)and8-iso-prostaglandinF2α plasma of patients with breast cancer and compare with controls .In this study ;  the mean MDA (ng/ml) levels for the breast cancer patients and the controls were55.91±3.31 and40.61±3.76  respectively, while the SOD (pg/ml) levels were1530.37±80.4 and1851.4 9±93.65  respectively and the 8-iso-PGF2α (ng/ml ) levels were 40.16±3.31 and 30.16±2.34  difference of the mean were statistically significant (p value <0.05).                                                                                                                       

scholarly journals Hubungan Dukungan Keluarga Terhadap Kualitas Hidup Pasien Kanker Payudara di Rumah Sakit Islam Siti Khodijah Palembang Tahun 2018

2019 ◽  
Vol 19 (3) ◽  
pp. 529
Author(s):  
Yofa Anggriani Utama
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Developing Countries ◽  
Family Support ◽  
Cancer Patients ◽  
Sampling Technique ◽  
P Value ◽  
Breast Cancer Patients ◽  
The World

Cancer is one of the causes of death in both developed and developing countries, cancer is increasing in developing countries due to increasing lifestyle, breast cancer is a cancer that causes death in women in the world, breast cancer is the highest contributor to mortality in women in the world, 43.3 per 100,000. The purpose of this study was to determine the relationship of family support to the quality of life of breast cancer patients. The research design used was observational analytic with cross sectional approach. The sampling technique used purposive sampling technique, the study sample amounted to 63 breast cancer patients. The results show that there is a relationship between family support and the quality of life of breast cancer patients with a p value of 0.032. shows there is a relationship between family support for the quality of life of patients with breast cancer. Suggestions that nurses can improve the quality of nursing services, and provide motivation to patients and families of breast cancer in carrying out breast cancer treatment.

scholarly journals Relationship between platelet-lymphocyte ratio and tumour infiltrating lymphocyte on metastatic in breast cancer patient

2019 ◽  
Vol 7 (6) ◽  
pp. 2045
Author(s):  
Indro Wibowo Sejati ◽  
Ida Bagus Tjakra Wibawa Manuaba ◽  
Putu Anda Tusta ◽  
Gede Budhi Setiawan
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Cancer Metastasis ◽  
Breast Cancer Subtype ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Sample Group ◽  
Lymphocyte Ratio ◽  
Platelet Lymphocyte Ratio

Background: Platelet-lymphocyte ratio (PLR) is known associated with the prognosis of distant metastatic breast cancer. Tumor-infiltrating lymphocyte (TIL) in breast cancer also associated with the prognosis of distant metastatic breast cancer. In this study, we will examine the relationship between PLR and TIL, in association with the metastatic incidence in breast cancer.Methods: This research is a retrospective, analytic, cross-sectional study. Data was taken from medical records of breast cancer patients at Sanglah general hospital. Samples were taken by nested sampling by selecting all breast cancer patients from the period of January 1st, 2017, to December 31st, 2018, which had complete medical record data, with total sample 211. The PLR and TIL were calculated and analyzed in relation to metastasis incidence of breast cancer.Results: The sample characteristics were sorted by age, education, occupation, the area of origin, menstrual status, breast cancer staging, breast cancer subtype, TIL levels, lymphovascular invasion (LVI) status, metastatic status, and breast cancer grading. The data were analyzed to know the association of PLR, TIL, confounding factors in relation to metastatic incidences. In the sample group with PLR ≥ 156 10µ /µL, there were 22.9% cases of metastases (p = 0.002). The sample group at low TIL had metastatic event 12.5% with (p=0.442).Conclusions: PLR was associated with higher metastasis in breast cancer patients and low TIL had no association with breast cancer metastasis.

scholarly journals PENGARUH LATIHAN JALAN KAKI TERHADAP KUALITAS TIDUR PADA PASIEN KANKER PAYUDARA YANG MENJALANI KEMOTERAPI DI RSUP DR. M DJAMIL PADANG

2020 ◽  
Vol 3 (1) ◽  
pp. Page16-27
Author(s):  
Weny Amelia ◽  
Mira Andika ◽  
Diana Yulanda
Keyword(s):  
Breast Cancer ◽  
Sleep Quality ◽  
Cancer Patients ◽  
Quality Index ◽  
Quality Score ◽  
P Value ◽  
Breast Cancer Patients ◽  
Quality Of Sleep ◽  
Walking Exercise

Abstrak Kemoterapi merupakan salah satu modalitas pengobatan kanker untuk mengatasi stadium lokal maupun metastase. Masalah yang sering muncul pada pasien kanker payudara yang menjalani kemoterapi adalah gangguan tidur sehingga berpengaruh terhadap kualitas tidur pasien. Penurunan kualitas tidur yang dialami oleh pasien kanker payudara yang menjalani kemoterapi dapat diatasi dengan latihan jalan kaki. Latihan jalan kaki merupakan kegiatan atau aktivitas yang dilakukan dengan menggunakan kedua kaki yang diikuti dengan ayunan tangan atau bagian anggota tubuh secara sinergis. Tujuan penelitian ini adalah untuk melihat pengaruh latihan jalan kaki terhadap kualitas tidur padapasien kanker payudara yang menjalani kemoterapi.                    . Penelitian ini dilakukan di RSUP Dr. M.Djamil Padang. Waktu penelitian ini dimulai pada tanggal 4-9 September 2019. Penelitian ini menggunakan pre eksperimet design dengan rancangan one group pretest-posttest design. Pengumpulan data dilakukan dengan menggunakan kuesioner PSQI (Pittsburgh Quality Index) untuk mengetahui kualitas tidur pasien berupa latihan jalan kaki selama 30 menit dilakukan 3 kali dalam 3 hari. .                       Hasil penelitian dengan uji statistik uji paired sampel t-test didapatkan bahwa rata-rata skor kualitas tidur sebelum intervensi 12.16 dan rata-rata skor kualitas tidur setelah intervensi 7.16. Penelitian ini menemukan perbedaan bermakna peningkatan kualitas tidur sebelum dan setelah intervensi p value = 0,000 ( p< 0.05) sehingga dapat disimpulkan bahwa terdapat pengaruh latihan jalan kaki terhadap kualitas tidur pasien kanker payudara yang menjalani kemoterapi.                                       .                                                       Disarankan kepada perawat untuk memberikan edukasi latihan jalan kaki kepada pasien kanker payudara yang menjalani kemoterapi untuk meningkatkan kualitas tidur pasien, sehingga dapat meningkatkan kondisi kesehatan pasien secara umum yang nantinya dapat memperbaiki dan meningkatkan kualitas hidup pasien kanker payudara. Kata Kunci : Latihan Jalan kaki, Kualitas Tidur,  Kanker Payudara, Kemoterapi Abstract                     Chemotherapy is one of the modalities of cancer treatment to overcome the local stage and metastasis. The problem that often arises in breast cancer patients undergoing chemotherapy is sleep disorders that affect the patient's sleep quality. Decreased sleep quality experienced by breast cancer patients undergoing chemotherapy can be overcome by walking exercises. Walking exercises are activities or activities carried out using both legs followed by swinging hands or parts of the body synergistically. The purpose of this study was to look at the effect of walking training on sleep quality in breast cancer patients undergoing chemotherapy. .                     This research was conducted at the Dr. M.Djamil Padang. When this study began on September 4-9, 2019. This study used a pre-experimental design with one group pretest-posttest design. Data collection was carried out using a PSQI (Pittsburgh Quality Index) questionnaire to determine the quality of sleep of patients in the form of 30 minutes of walking exercises performed 3 times in 3 days. .                     The results of the study with the statistical test paired sample t-test found that the average sleep quality score before the intervention was 12.16 and the average sleep quality score after the intervention was 7.16. This study found a significant difference in the improvement of sleep quality before and after the intervention p value = 0,000 (p <0.05) so that it can be concluded that there is an effect of walking exercise on the sleep quality of breast cancer patients undergoing chemotherapy. .                     It is recommended to nurses to provide education on walking exercises to breast cancer patients undergoing chemotherapy to improve the quality of sleep of patients, so as to improve the general health condition of patients who can later improve and improve the quality of life for breast cancer patients. Keywords: Breast Cancer, Chemotherapy, Sleep Quality, Walking Exercise

Profiling receptor tyrosine kinase fusions in Chinese breast cancers.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15092-e15092
Author(s):  
Zhonghua Tao ◽  
Xichun Hu ◽  
Wen-Ming Cao ◽  
Jianxia Liu ◽  
Ting Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Tyrosine Kinase ◽  
Cancer Patients ◽  
Tyrosine Kinases ◽  
Breast Cancer Subtype ◽  
Stage Iv ◽  
Tyrosine Kinase Domain ◽  
Breast Cancers ◽  
Breast Cancer Patients ◽  
Her2 Positive

e15092 Background: Receptor tyrosine kinases (RTKs) are a class of tyrosine kinases that regulate cell-to-cell communication and control a variety of complex biological functions. Dysregulation of RTK signaling partly due to chromosomal rearrangements leads to novel tyrosine kinase fusion oncoproteins which are possibly driver alterations to cancers. Targeting some RTK fusions with specific tyrosine kinases inhibitors (TKIs) is an effective therapeutic strategy across a spectrum of RTK fusion-related cancers. However, there is still a paucity of extensive RTK fusion investigations in breast cancer. We aimed to characterize RTK fusions in Chinese breast cancer patients. Methods: An in-house sequencing database of 1440 Chinese breast cancer patients using a 520-gene NGS sequencing panel was thoroughly reviewed. RTK fusion was defined as an in-frame fusion with the tyrosine kinase domain of the RTK completely retained with the only exception of ERBB2 fusion which was not counted due to its unclear significance. Concomitant mutations and TMB were also analyzed and calculated. Patients’ clinical characteristics were retrieved from case records. Results: 27 RTK fusion-positive breast cancers (12 tissues + 15 plasmas) were identified, patients had a median age of 52 years. Triple-negative breast cancer subtype comprised 37% with luminal and HER2 positive subtypes being 40.8% and 22.2%, respectively. 77.8% of patients were at stage IV and 22.2% at stage I-III. Ten were treatment naïve. RTK fusions occurred in 2% of breast cancers in our database, compared with the prevalence of 0.6% and 1.3% in MSKCC and TCGA, respectively. In the subset of stage IV patients, our database showed a significantly higher RTK fusion frequency than that in MSKCC (3.2% vs. 0.6%, p = 0.013). FGFR2 fusions were seen most commonly (n = 7), followed by RET (n = 4), ROS1 (n = 3), NTRK3 (n = 3), BRAF (n = 2), and NTRK1 (n = 2). Other RTK fusions including ALK, EGFR, FGFR1, FGFR3, MET, and NTRK2 were identified in one patient each. Of note, the normalized abundance of RTK fusion (fusion AF/max AF) correlated negatively with TMB (r = -0.48, p = 0.017). Patients with TMB < 4 (Muts/Mb) displayed a higher fusion abundance than those with TMB ≥ 4 (Muts/Mb) (p = 0.018), suggesting a higher likelihood of subclonal nature for RTK fusions in TMB-high patients. Moreover, CREBBP mutation only co-occurred with FGFR2 fusion (p = 0.012), while NTRK3 fusion and TP53 mutation were mutually exclusive (p = 0.019). Conclusions: This is the first study comprehensively delineating the prevalence and spectrum of RTK fusions in Chinese breast cancers. Further study is ongoing to identify the enriched subpopulation which may benefit from RTK fusion inhibitors.

COVID-related anxiety is prevalent and accurately reflects serious COVID risks in breast cancer patients.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 12053-12053
Author(s):  
Marisa C. Weiss ◽  
Stephanie Kjelstrom ◽  
Meghan Buckley ◽  
Adam Leitenberger ◽  
Melissa Jenkins ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Breast Cancer Diagnosis ◽  
P Value ◽  
Breast Cancer Patients ◽  
Chi Square ◽  
Liver And Kidney ◽  
Chi Square Test ◽  
A Current

12053 Background: A current cancer diagnosis is a risk factor for serious COVID-19 complications (CDC). In addition, the pandemic has caused major disruptions in medical care and support networks, resulting in treatment delays, limited access to doctors, worsening health disparities, social isolation; and driving higher utilization of telemedicine and online resources. Breastcancer.org has experienced a sustained surge of new and repeat users seeking urgent information and support. To better understand these unmet needs, we conducted a survey of the Breastcancer.org Community. Methods: Members of the Breastcancer.org Community were invited to complete a survey on the effects of the COVID-19 pandemic on their breast cancer care, including questions on demographics, comorbidities (including lung, heart, liver and kidney disease, asthma, diabetes, obesity, and other chronic health conditions); care delays, anxiety due to COVID-related care delays, use of telemedicine, and satisfaction with care during COVID. The survey was conducted between 4/27/2020-6/1/2020 using Survey Monkey. Results were tabulated and compared by chi square test. A p-value of 0.05 is considered significant. Data were analyzed using Stata 16.0 (Stata Corp., Inc, College Station, TX). Results: Our analysis included 568 breast cancer patients of whom 44% had ≥1 other comorbidities associated with serious COVID-19 complications (per CDC) and 37% had moderate to extreme anxiety about contracting COVID. This anxiety increased with the number of comorbidities (p=0.021), age (p=0.040), and with a current breast cancer diagnosis (p=0.011) (see table). Anxiety was significantly higher in those currently diagnosed, ≥65, or with ≥3 other comorbidities, compared to those diagnosed in the past, age <44, or without other comorbidities. Conclusions: Our survey reveals that COVID-related anxiety is prevalent at any age regardless of overall health status, but it increased with the number of other comorbidities, older age, and a current breast cancer diagnosis. Thus, reported anxiety is proportional to the risk of developing serious complications from COVID. Current breast cancer patients of all ages—especially with other comorbidities—require emotional support, safe access to their providers, and prioritization for vaccination.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document